//knekt.tv/knekttv-en/video/knekttvarchive/64201/64204-season-1/132954-fsd-pharma-signs-binding-loi-to-acquire-nasdaq-listed-therapix-biosciences

KNEKT®tv

HomeInvestment Pitch FSD Pharma signs binding LOI to acquire NASDAQ-listed Therapix Biosciences

FSD Pharma signs binding LOI to acquire NASDAQ-listed Therapix Biosciences

Investment Pitch | Season 1

Therapix is currently repurposing an FDA-approved cannabinoid for the treatment of central nervous system disorders, sleep disorders, pain management, mild cognitive impairment, traumatic brain injury and infectious diseases.